Development of transgenic mice that inducibly express an active form of c‐Src in the epidermis

Recent work from our laboratory has shown that elevated src kinase activity enhances tumor promotion, malignant progression, and metastasis during multistage skin carcinogenesis. In this study, we have generated “gene‐switch” src530 transgenic mice to further analyze the role of this nonreceptor tyrosine kinase in multistage carcinogenesis. Target transgenic mice that have an activated form of the human c‐src (src530) gene fused with GAL4 binding sites upstream of the thymidine kinase (TK) promoter were generated. Two lines of epidermis‐specific transactivator mice were used that targeted the expression of GLVPc or GLp65 transactivators, fusion molecules containing a truncated progesterone receptor with a GAl4‐DNA binding domain, with either a mouse loricrin (ML) or human keratin 14 (HK14) promoter, respectively. The transactivator mice (ML.GLVPc or HK14.GLp65) and the target mice (TK.src530) were mated to generate bitransgenic mice, and src530 transgene expression was induced by topical application of RU486 (mifepristone, a progesterone receptor antagonist). In both ML.GLVPc/TK.src530 and HK14.GLp65/TK.src530 bitransgenic mice, histological analysis revealed that only the bitransgenic mice had marked epidermal hyperplasia and hyperkeratosis after treatment with RU486. Neither the nontransgenic mice nor the mice hemizygous for either the transactivator transgene or the target transgene alone showed any response to treatment with RU486. In addition, no differences were observed in the skin of the bitransgenic mice versus nontransgenic littermates without treatment of RU486. Interestingly, in HK14.GLp65/TK.src530 bitransgenic mice, squamous cell carcinomas (SCCs) arose along the periphery of the area of the punch biopsies in 25% of the bitransgenic mice several weeks after taking the biopsy and subsequent to RU486 treatment. Collectively, the data support a role of c‐src activation in epidermal hyperproliferation. Furthermore, the data support the conclusion that src activation can substitute for an initiating event in the presence of a tumor promoting stimulus (i.e., wounding). Finally, inducible src530 transgenic mice provide a new tool for dissecting the role of src activation in multistage carcinogenesis by allowing temporal control of the expression of this oncogene. © 2004 Wiley‐Liss, Inc.

[1]  J. Clifford,et al.  Epidermal Growth Factor Receptor-Mediated Activation of Stat3 during Multistage Skin Carcinogenesis , 2004, Cancer Research.

[2]  Takashi Matsumoto,et al.  Targeted expression of c-Src in epidermal basal cells leads to enhanced skin tumor promotion, malignant progression, and metastasis. , 2003, Cancer research.

[3]  Hua Yu,et al.  Roles of activated Src and Stat3 signaling in melanoma tumor cell growth , 2002, Oncogene.

[4]  Takashi Matsumoto,et al.  Overexpression of a constitutively active form of c‐src in skin epidermis increases sensitivity to tumor promotion by 12‐O‐tetradecanoylphorbol‐13‐acetate , 2002, Molecular carcinogenesis.

[5]  D. Roop,et al.  K14‐GLp65 transactivator induces transgene expression in embryonic epidermis , 2002, Genesis.

[6]  B. Weeks,et al.  Inducible expression of transforming growth factor beta1 in papillomas causes rapid metastasis. , 2001, Cancer research.

[7]  J. Turkson,et al.  Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling , 2000, Oncogene.

[8]  J. Grandis,et al.  Epidermal Growth Factor Receptor–Mediated Stat3 Signaling Blocks Apoptosis in Head and Neck Cancer , 2000, The Laryngoscope.

[9]  K. Mokbel,et al.  The effect of surgical wounding on tumour development. , 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[10]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[11]  R. Jove,et al.  Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors , 1999, Oncogene.

[12]  B. O’Malley,et al.  Development of gene-switch transgenic mice that inducibly express transforming growth factor beta1 in the epidermis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Parsons,et al.  Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[14]  B. O’Malley,et al.  Adenovirus-mediated regulable target gene expression in vivo. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Darnell,et al.  Stat3 Activation Is Required for Cellular Transformation by v-src , 1998, Molecular and Cellular Biology.

[16]  H. Friess,et al.  Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. , 1998, Biochemical and biophysical research communications.

[17]  J. Jorcano,et al.  Severe follicular hyperplasia and spontaneous papilloma formation in transgenic mice expressing the neu oncogene under the control of the bovine keratin 5 promoter , 1998, Molecular carcinogenesis.

[18]  Y. Wang,et al.  Positive and negative regulation of gene expression in eukaryotic cells with an inducible transcriptional regulator , 1997, Gene Therapy.

[19]  D. Bol,et al.  Overexpression of insulin-like growth factor-1 induces hyperplasia, dermal abnormalities, and spontaneous tumor formation in transgenic mice , 1997, Oncogene.

[20]  J. DiGiovanni,et al.  Activation of erbB2 and c-src in phorbol ester-treated mouse epidermis: possible role in mouse skin tumor promotion , 1997, Oncogene.

[21]  D. Nathans,et al.  In vitro activation of Stat3 by epidermal growth factor receptor kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. T. Brown,et al.  Regulation, substrates and functions of src. , 1996, Biochimica et biophysica acta.

[23]  W. Muller,et al.  Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor. , 1995, Oncogene.

[24]  M. Maa,et al.  Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[25]  H. Vogel,et al.  Combined deficiencies of Src, Fyn, and Yes tyrosine kinases in mutant mice. , 1994, Genes & development.

[26]  Y Wang,et al.  A regulatory system for use in gene transfer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  W. Muller,et al.  Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity , 1994, Molecular and cellular biology.

[28]  J. DiGiovanni,et al.  C57BL/6 mice are resistant to tumor promotion by full thickness skin wounding. , 1993, Carcinogenesis.

[29]  G. Staal,et al.  Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. , 1992, Cancer research.

[30]  Brickell Pm The p60c-src family of protein-tyrosine kinases: structure, regulation, and function. , 1992 .

[31]  J. DiGiovanni,et al.  Multistage carcinogenesis in mouse skin. , 1992, Pharmacology & therapeutics.

[32]  H. Varmus,et al.  Mutations in src homology regions 2 and 3 of activated chicken c-src that result in preferential transformation of mouse or chicken cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Peter K. Vogt,et al.  Obligatory wounding requirement for tumorigenesis in v-jun transgenic mice , 1990, Nature.

[34]  M. Sporn,et al.  Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-beta. , 1990, Science.

[35]  H. Wanebo,et al.  The influence of the surgical wound on local tumor recurrence. , 1989, Surgery.

[36]  J. Pipas,et al.  pp60c-src activation in human colon carcinoma. , 1989, The Journal of clinical investigation.

[37]  M. Okada,et al.  Identification of a novel protein tyrosine kinase that phosphorylates pp60c-src and regulates its activity in neonatal rat brain. , 1988, Biochemical and biophysical research communications.

[38]  I. Brody Changes in keratinocyte maturation during wound healing. , 1988, The Journal of investigative dermatology.

[39]  M. Sheppard Pharmacology and Clinical Uses of Inhibitors of Hormone Secretion and Action , 1988 .

[40]  J. DiGiovanni,et al.  Comparison of the histological changes in the skin of DBA/2 and C57BL/6 mice following exposure to various promoting agents. , 1987, Carcinogenesis.

[41]  C. Molloy,et al.  Specific alterations in keratin biosynthesis in mouse epidermis in vivo and in explant culture following a single exposure to the tumor promoter 12-O-tetradecanoylphorbol-13-acetate. , 1987, Cancer research.

[42]  P. Cohen,et al.  Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. , 1986, The Journal of biological chemistry.

[43]  J. Brugge,et al.  A normal cell protein similar in structure and function to the avian sarcoma virus transforming gene product. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[44]  J. Brugge,et al.  Identification of a transformation-specific antigen induced by an avian sarcoma virus , 1977, Nature.

[45]  L. Dunham Cancer in man at site of prior benign lesion of skin or mucous membrane: a review. , 1972, Cancer research.

[46]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[47]  P. Fitzpatrick [Tumors of the skin]. , 1967, L' Infirmiere canadienne.